Glenmark Pharmaceuticals Receives U.S. FDA Approval for Fluticasone Propionate Nasal Spray

Glenmark Pharmaceuticals Limited has announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Fluticasone Propionate Nasal Spray USP, 0.05 mg (50 mcg)/spray. The approval was announced on August 20, 2026, and marks another addition to the company’s respiratory portfolio in the U.S. market.

Glenmark’s Fluticasone Propionate Nasal Spray is bioequivalent and therapeutically equivalent to Flonase Nasal Spray 0.05 mg/spray, the reference listed drug of Haleon US Holdings LLC under NDA 020121. The product will be distributed in the United States through Glenmark Pharmaceuticals Inc., USA.

U.S. Market Opportunity

According to IQVIA sales data for the 12 months ended June 2026, the market for Flonase Nasal Spray, including the brand and available therapeutic equivalents, recorded annual sales of approximately $295.2 million.

The company said the approval provides an opportunity to further expand its presence in the U.S. respiratory segment. Glenmark noted that the product will be marketed only for the indications included in its approved U.S. label.

Glenmark Expands Respiratory Portfolio

Commenting on the approval, Marc Kikuchi, President & Business Head, North America, said the approval represents another step in expanding Glenmark’s respiratory portfolio in the United States. He added that the company intends to build on its existing position in the therapeutic area while expanding access to quality and affordable treatment options for patients and healthcare providers.

The approval is particularly relevant to Glenmark’s strategy of strengthening its presence in respiratory therapies, one of the company’s key focus areas.

What the FDA Approval Means for Glenmark

The approval strengthens Glenmark’s U.S. product portfolio and provides access to a sizable market opportunity. The company has an established presence in the U.S. pharmaceutical market, and additional respiratory products can support the diversification of its product offering.

However, the reported $295.2 million market size represents the total market for the brand and available therapeutic equivalents, rather than Glenmark’s expected sales from the product. Actual commercial performance will depend on factors including market competition, pricing, distribution and prescription demand.

Glenmark Pharmaceuticals: Global Presence

Glenmark Pharmaceuticals is a research-led pharmaceutical company focused on innovation and accessibility. Its portfolio spans branded, innovative, generic and consumer healthcare products, with key therapeutic focus areas including respiratory diseases, dermatology and oncology.

The company operates 11 manufacturing facilities across four continents, supported by six R&D centres, and has a commercial presence in more than 80 countries.

Stock Market Impact

The U.S. FDA approval is a positive business development for Glenmark Pharmaceuticals, as it adds another approved product to the company’s U.S. portfolio and provides exposure to the respiratory nasal spray market.

Investors may monitor the company’s subsequent launch plans, pricing, competitive environment, and contribution from the product to U.S. revenues. The immediate stock-market reaction, however, will depend on how investors assess the commercial opportunity and the potential financial contribution of the approval.

Key Takeaways

• Glenmark received U.S. FDA approval for Fluticasone Propionate Nasal Spray USP 0.05 mg/spray.
• The product is bioequivalent and therapeutically equivalent to Flonase Nasal Spray 0.05 mg/spray.
• Glenmark Pharmaceuticals Inc., USA will distribute the product in the U.S.
• The Flonase market recorded approximately $295.2 million in annual sales for the 12 months ended June 2026, according to IQVIA.
• The approval strengthens Glenmark’s U.S. respiratory portfolio.
• Investors will watch the product launch, competitive intensity, and potential revenue contribution.

Disclaimer: This article is based on Glenmark Pharmaceuticals Limited’s corporate disclosure dated August 20, 2026. The reported market size is not a projection of Glenmark’s sales, and the article should not be considered investment advice.

Glenmark Pharmaceuticals Limited has announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Fluticasone Propionate Nasal Spray USP, 0.05 mg (50 mcg)/spray. The approval was announced on August 20, 2026, and marks another addition to the company’s respiratory portfolio in the U.S. market.

Glenmark’s Fluticasone Propionate Nasal Spray is bioequivalent and therapeutically equivalent to Flonase Nasal Spray 0.05 mg/spray, the reference listed drug of Haleon US Holdings LLC under NDA 020121. The product will be distributed in the United States through Glenmark Pharmaceuticals Inc., USA.

U.S. Market Opportunity

According to IQVIA sales data for the 12 months ended June 2026, the market for Flonase Nasal Spray, including the brand and available therapeutic equivalents, recorded annual sales of approximately $295.2 million.

The company said the approval provides an opportunity to further expand its presence in the U.S. respiratory segment. Glenmark noted that the product will be marketed only for the indications included in its approved U.S. label.

Glenmark Expands Respiratory Portfolio

Commenting on the approval, Marc Kikuchi, President & Business Head, North America, said the approval represents another step in expanding Glenmark’s respiratory portfolio in the United States. He added that the company intends to build on its existing position in the therapeutic area while expanding access to quality and affordable treatment options for patients and healthcare providers.

The approval is particularly relevant to Glenmark’s strategy of strengthening its presence in respiratory therapies, one of the company’s key focus areas.

What the FDA Approval Means for Glenmark

The approval strengthens Glenmark’s U.S. product portfolio and provides access to a sizable market opportunity. The company has an established presence in the U.S. pharmaceutical market, and additional respiratory products can support the diversification of its product offering.

However, the reported $295.2 million market size represents the total market for the brand and available therapeutic equivalents, rather than Glenmark’s expected sales from the product. Actual commercial performance will depend on factors including market competition, pricing, distribution and prescription demand.

Glenmark Pharmaceuticals: Global Presence

Glenmark Pharmaceuticals is a research-led pharmaceutical company focused on innovation and accessibility. Its portfolio spans branded, innovative, generic and consumer healthcare products, with key therapeutic focus areas including respiratory diseases, dermatology and oncology.

The company operates 11 manufacturing facilities across four continents, supported by six R&D centres, and has a commercial presence in more than 80 countries.

Stock Market Impact

The U.S. FDA approval is a positive business development for Glenmark Pharmaceuticals, as it adds another approved product to the company’s U.S. portfolio and provides exposure to the respiratory nasal spray market.

Investors may monitor the company’s subsequent launch plans, pricing, competitive environment, and contribution from the product to U.S. revenues. The immediate stock-market reaction, however, will depend on how investors assess the commercial opportunity and the potential financial contribution of the approval.

Key Takeaways

• Glenmark received U.S. FDA approval for Fluticasone Propionate Nasal Spray USP 0.05 mg/spray.
• The product is bioequivalent and therapeutically equivalent to Flonase Nasal Spray 0.05 mg/spray.
• Glenmark Pharmaceuticals Inc., USA will distribute the product in the U.S.
• The Flonase market recorded approximately $295.2 million in annual sales for the 12 months ended June 2026, according to IQVIA.
• The approval strengthens Glenmark’s U.S. respiratory portfolio.
• Investors will watch the product launch, competitive intensity, and potential revenue contribution.

Disclaimer: This article is based on Glenmark Pharmaceuticals Limited’s corporate disclosure dated August 20, 2026. The reported market size is not a projection of Glenmark’s sales, and the article should not be considered investment advice.